Thank you for participating in the BIC 2023!

The BIC International Conference is traditionally addressed to a relatively narrow selection of medical specialties since it is meant to feature only the most novel advances of basic science and clinical research in haemophilia, rare inherited coagulation disorders, von Willebrand factor and von Willebrand disease, gene therapy, the thrombotic microangiopathies and, of course, factor VIII inhibitors. The 2023 edition will have a major focus on the latest update on second generation gene therapy for both haemophilias.

The BIC Conference, that has been organized for many years starting as early as in 1983 by the leading staff of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milan, has gained a reputation among the scientists and clinicians interested in haemostasis and inherited bleeding disorders. In the last decade and particularly in the last few years there have been spectacular advances in this field, stemming from basic science that led to translation implications pertaining the treatment of patients. With this background, a blend of new discoveries in both basic and clinical science will be featured by the invited speakers, chosen by the International Scientific Committee among those scientists that are committing to present new data as yet unpublished and discuss them with their peers. In addition to the scientific sessions, it is a tradition of the BIC Conference to have lively sessions based upon original abstracts competitively submitted by investigators other than those invited by the Scientific Committee. Moreover, pharmaceutical companies will have the opportunity to organize a limited number of sponsored satellite sessions, that are particularly cogent and welcome at a time when so many amazing novelties are occurring for the management of those diseases that are the nugget of the conference. On the whole, the well consolidated format of this conference should be a guarantee of attraction for scientists and clinicians interested in haemostasis and bleeding disorders.